The iconic rise of copyright’s flagship product presented a significant chance for shareholders , but its period has expired , creating a challenging landscape. Generic versions have entered the market , diminishing sales and putting a squeeze on profit margins . While established drug companies hold a stake in this field , the outlook remains cl